ALG8

Across TCGA pan-cancer cohorts, ALG8 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ALG8’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ALG8 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ALG8 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

CCRCC, LSCC, and PDAC are the cancer types where ALG8 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ALG8 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	III,IV	+0.380	<.001	9	view →
LSCC	Male	All	+0.558	<.001	8	view →
PDAC	All	All	−0.921	<.001	6	view →
LUAD	Female	All	+0.507	<.001	6	view →
HNSC	All	IV	+0.340	.021	5	view →
COAD	All	All	+0.237	<.001	4	view →
OV	All	All	+0.434	.013	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ALG8–CCRCC

Open the CCRCC breakdown →